LLY

1,039.57

+3.11%↑

JNJ

230.44

+0.17%↑

ABBV

215.27

+1.25%↑

UNH

383.89

+0.35%↑

AZN

189.87

+1%↑

LLY

1,039.57

+3.11%↑

JNJ

230.44

+0.17%↑

ABBV

215.27

+1.25%↑

UNH

383.89

+0.35%↑

AZN

189.87

+1%↑

LLY

1,039.57

+3.11%↑

JNJ

230.44

+0.17%↑

ABBV

215.27

+1.25%↑

UNH

383.89

+0.35%↑

AZN

189.87

+1%↑

LLY

1,039.57

+3.11%↑

JNJ

230.44

+0.17%↑

ABBV

215.27

+1.25%↑

UNH

383.89

+0.35%↑

AZN

189.87

+1%↑

LLY

1,039.57

+3.11%↑

JNJ

230.44

+0.17%↑

ABBV

215.27

+1.25%↑

UNH

383.89

+0.35%↑

AZN

189.87

+1%↑

Home・Elenco Azioni・Erasca Inc

Erasca Inc

Aperta

11.64 3.19

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.92

Massimo

11.64

Metriche Chiave
By Trading Economics
Entrata	-154M -183M
EPS	-0.6
Dipendenti	103
EBITDA	-5.3M -37M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+82.28% upside

Dividendi
By Dow Jones
Utili prossimi	10 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-53M 3.2B
Apertura precedente	8.45
Chiusura precedente	11.64

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

1.39 / 1.44 Supporto e resistenza

Erasca Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 mag 2026, 23:31 UTC

Azioni calde

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 mag 2026, 22:52 UTC

I principali Market Mover

Osisko Shares Fall on Planned Convertible Notes Offering

20 mag 2026, 23:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

20 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 mag 2026, 23:44 UTC

Utili

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 mag 2026, 23:35 UTC

Discorsi di Mercato

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 mag 2026, 23:30 UTC

Discorsi di Mercato

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 mag 2026, 23:17 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

20 mag 2026, 23:17 UTC

Discorsi di Mercato

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 mag 2026, 23:15 UTC

Discorsi di Mercato

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 mag 2026, 23:14 UTC

Utili

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 mag 2026, 23:02 UTC

Discorsi di Mercato

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 mag 2026, 22:57 UTC

Discorsi di Mercato

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 mag 2026, 22:57 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

20 mag 2026, 22:57 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

20 mag 2026, 22:51 UTC

Discorsi di Mercato

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 mag 2026, 22:51 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

20 mag 2026, 22:27 UTC

Discorsi di Mercato

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 mag 2026, 22:14 UTC

Discorsi di Mercato

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 mag 2026, 22:10 UTC

Utili

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 mag 2026, 22:00 UTC

Utili

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 mag 2026, 21:38 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 mag 2026, 21:27 UTC

Utili

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 mag 2026, 21:20 UTC

Utili

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 mag 2026, 21:19 UTC

Utili

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 mag 2026, 21:18 UTC

Utili

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 mag 2026, 21:17 UTC

Utili

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 mag 2026, 21:17 UTC

Utili

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 mag 2026, 21:17 UTC

Utili

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 mag 2026, 21:16 UTC

Utili

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Erasca Inc Previsione

Obiettivo di Prezzo

By TipRanks

82.28% in crescita

Previsioni per 12 mesi

Media 20.27 USD 82.28%

Alto 30 USD

Basso 9 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Erasca Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Erasca Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

1.39 / 1.44Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.